12 Best Low Price Pharma Stocks To Invest In Right Now

Page 9 of 10

2. Grifols, S.A. (NASDAQ:GRFS)

Share Price as of the Close of February 21: $7.45

Grifols, S.A. (NASDAQ:GRFS) is a Spanish global healthcare company specializing in plasma-derived therapies, diagnostics, and hospital pharmacy products. The company was founded in 1909 in Barcelona and it develops and markets biological medicines for rare and life-threatening conditions. The company operates through five divisions: Bioscience (plasma-derived therapies), Diagnostic (in vitro diagnostics), Hospital (medical technology and medicines), Bio Supplies (biological products for non-therapeutic use), and others. Its core business revolves around plasma-based treatments for chronic diseases.

Grifols, S.A. (NASDAQ:GRFS) delivered strong financial results in Q3 2024, showing solid growth and improved financial health. Revenue reached EUR 1,793 million, reflecting a 12.4% year-over-year increase. Adjusted EBITDA grew by 26.7% to EUR 462 million, with a healthy margin of 26%. Free cash flow saw a significant boost to EUR 127 million, and the company successfully lowered its leverage ratio from 6.8x in Q1 to 5.1x in Q3, indicating better debt management.

Grifols, S.A. (NASDAQ:GRFS)’s Biopharma division performed well, growing by 12.1% in Q3. The Immunoglobulin (IG) Franchise saw a strong 16.6% increase, with subcutaneous IG experiencing a remarkable 52% growth year-to-date. Albumin sales also rose by 11.7%, further strengthening Grifols’ position in the plasma-derived medicines market.

Grifols, S.A. (NASDAQ:GRFS) remains a market leader in plasma-derived therapies, benefiting from rising global demand. The company continues to improve its financial performance by increasing revenue, expanding profit margins, and reducing debt. Its focus on innovation is evident through its recent contract with the US BARDA to develop a recombinant polyclonal antibody therapeutic platform. With a strong presence in key international markets like China, Grifols, S.A. (NASDAQ:GRFS) is well-positioned for long-term growth.

Page 9 of 10